scholarly journals Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy

2020 ◽  
Author(s):  
Zhiqiang Wu ◽  
Wenbo Guo ◽  
Song Chen ◽  
Wenquan Zhuang
Keyword(s):  
Hepatic Artery ◽  
Linear Regression Analysis ◽  
Hepatic Artery Infusion ◽  
Multivariate Linear Regression Analysis ◽  
Preparation Time ◽  
Advanced Hcc ◽  
Infusion Chemotherapy ◽  
Vas Score ◽  
Hepatic Artery Infusion Chemotherapy ◽  
Lidocaine Injection

Summary Purpose Hepatic arterial infusion chemotherapy (HAIC) is one of the options to treat unresectable hepatocellular carcinoma (HCC). The majority of HCC patients suffer great pain in the course of HAIC treatment. To improve the quality of life and the efficacy of HAIC treatment, the causes of pain, the choice of an analgesic regimen, and the relationship between pain and prognosis of HCC were analyzed. Methods A total of 376 HCC patients under HAIC in our hospital were recriuted between March 2017 and September 2019. Multivariate linear regression analysis (stepwise) was used to calculate the potential factors related to the severe pain in HCC patients under HAIC. Analgesics treatments were carried out based on the results of the visual analogue scale (VAS) score which was used to evaluate the pain. Results The mean value of the VAS score is 3.604, which indicates that the pain in most patients is mild and endurable. Intra-arterial lidocaine injection is an effective method in most patients (96%, 361 of 376), and the total score of VAS is reduced from 1355 to 195 following lidocaine injection. Multivariate analysis suggestes that oxaliplatin (OXA) preparation time, hepatic artery diameter and OXA manufacturers (R2 = 0.859) are influential factors for pain scores. Conclusion This study demonstrates an effective way to systematically assess and ease pain in HCC patients with HAIC treatment. OXA preparation time, hepatic artery diameter, and OXA manufacturers are the potential influencing factors for pain. This work presented here will provide a detailed understanding of the clinical application of HAIC in advanced HCC patients.

scholarly journals Effects of Antiviral Therapy on HBV Reactivation and Survival in Hepatocellular Carcinoma Patients Undergoing Hepatic Artery Infusion Chemotherapy

2021 ◽  
Vol 10 ◽  
Author(s):  
Shousheng Liu ◽  
Jinfa Lai ◽  
Ning Lyu ◽  
Qiankun Xie ◽  
Huijiao Cao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Hepatic Artery ◽  
Primary Hepatocellular Carcinoma ◽  
Hepatic Artery Infusion ◽  
Hbv Reactivation ◽  
Antiviral Prophylaxis ◽  
Advanced Hcc ◽  
Infusion Chemotherapy ◽  
Hepatic Artery Infusion Chemotherapy

BackgroundThis study aimed to investigate the influence of hepatic artery infusion chemotherapy (HAIC) on hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg) positive patients with primary hepatocellular carcinoma (HCC) as well as evaluate the role of antiviral prophylaxis in these patients.MethodsWe enrolled 170 HBsAg-positive advanced HCC patients receiving HAIC using mFOLFOX regimen, of which 137 patients received antiviral prophylaxis. Risk factors for HBV reactivation were analyzed. The overall survival (OS) from the first application of HAIC were compared between antiviral and non-antiviral groups.ResultsA total of 25 patients (14.7%) developed HBV reactivation after HAIC, of which 16 patients received antiviral treatment and nine patients did not. The incidence of HBV reactivation was 11.7% (16/137) in antiviral group and 27.3% (9/33) in non-antiviral group respectively. No antiviral prophylactic was the only significant risk factor for HBV reactivation (OR=12.35, 95% confidence interval (CI) 4.35–33.33, p<0.001). Patients in antiviral group received more cycles of HAIC compared with non-antiviral group (3.11 ± 1.69 vs 1.75 ± 1.18, p<0.05) at the time of HBV reactivated. Seven of the 25 HBV reactivation patients developed hepatitis. OS in antiviral group was significantly longer than that of non-antiviral group (median 16.46 vs 10.68 months; HR=0.57; 95% CI, 0.36–0.91; p<0.05).ConclusionsHBV reactivation is more prone to occur in the HBsAg-positive HCC patients undergoing HAIC without antiviral prophylaxis. Regular monitoring of HBV DNA and antiviral prophylaxis are suggested to prevent HBV reactivation as well as prolong the OS of these patients.Name of the Trial RegisterHAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients with Locally Advanced HCC.Clinical Trial Registrationhttps://www.clinicaltrials.gov/, identifier NCT 02436044

Causes of jaundice during hepatic artery infusion chemotherapy.

Radiology ◽  
1986 ◽  
Vol 161 (2) ◽  
pp. 439-442 ◽  
Author(s):  
S D Anderson ◽  
H C Holley ◽  
L L Berland ◽  
J A Van Dyke ◽  
R J Stanley
Keyword(s):  
Hepatic Artery ◽  
Hepatic Artery Infusion ◽  
Infusion Chemotherapy ◽  
Hepatic Artery Infusion Chemotherapy

Fatty Liver Change as a Result of Hepatic Artery Infusion Chemotherapy

1990 ◽  
Vol 13 (2) ◽  
pp. 156-160 ◽  
Author(s):  
Jacob Zeiss ◽  
Hollis W. Merrick ◽  
Edward R. Savolaine ◽  
Lee S. Woldenberg ◽  
Kitai Kim ◽  
...  
Keyword(s):  
Fatty Liver ◽  
Hepatic Artery ◽  
Hepatic Artery Infusion ◽  
Infusion Chemotherapy ◽  
Liver Change ◽  
Hepatic Artery Infusion Chemotherapy

scholarly journals Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Jie Mei ◽  
Yu-Hao Tang ◽  
Wei Wei ◽  
Ming Shi ◽  
Lie Zheng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Arterial Infusion ◽  
Progression Free Survival ◽  
Good Survival ◽  
Hepatic Artery Infusion ◽  
Advanced Hepatocellular Carcinoma ◽  
Advanced Hcc ◽  
Infusion Chemotherapy ◽  
Hepatic Artery Infusion Chemotherapy ◽  
Cell Death Protein

BackgroundLenvatinib combined with programmed cell death protein-1 (PD-1) inhibitors has resulted in good survival outcomes in the treatment of unresectable hepatocellular carcinoma (HCC). Hepatic artery infusion chemotherapy (HAIC) has also attracted attention due to its high response rates and favorable survival for advanced HCC patients. The present study aimed to compare the efficacy of HAIC combined with PD-1 inhibitors plus lenvatinib (HPL) and PD-1 inhibitors plus lenvatinib (PL) in patients with advanced HCC.MethodsBetween July 2018 and December 2019, patients diagnosed with advanced HCC who initially received HPL or PL treatment were reviewed for eligibility. Efficacy was evaluated according to tumor response and survival.ResultsIn total, 70 patients met the criteria and were included in the present study, and they were divided into the HPL group (n = 45) and PL group (n = 25). The overall response rate (40.0 vs. 16.0%, respectively; p = 0.038) and disease control rate (77.6 vs. 44.0%, respectively; p < 0.001) were higher in the HPL group than in the PL group. The median overall survival was 15.9 months in the HPL group and 8.6 months in the PL group (p = 0.0015; HR = 0.6; 95% CI 0.43–0.83). The median progression-free survival was 8.8 months in the HPL group and 5.4 months in the PL group (p = 0.0320; HR = 0.74; 95% CI 0.55–0.98).ConclusionCompared to PL, HPL was associated with a significantly better treatment response and survival benefits for patients with advanced HCC.

scholarly journals Hepatic artery-infusion chemotherapy improved survival of hepatocellular carcinoma after radical hepatectomy

2017 ◽  
Vol Volume 10 ◽  
pp. 3001-3005 ◽  
Author(s):  
Min Feng ◽  
Chengwu Tang ◽  
Wenming Feng ◽  
Ying Bao ◽  
Yinyuan Zheng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Artery ◽  
Hepatic Artery Infusion ◽  
Infusion Chemotherapy ◽  
Hepatic Artery Infusion Chemotherapy

scholarly journals Modern Prospection for Hepatic Arterial Infusion Chemotherapy in Malignancies with Liver Metastases

2013 ◽  
Vol 2013 ◽  
pp. 1-11 ◽  
Author(s):  
Yi-Hsin Liang ◽  
Yu-Yun Shao ◽  
Jia-Yi Chen ◽  
Po-Chin Liang ◽  
Ann-Lii Cheng ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Hepatic Artery ◽  
Liver Tumors ◽  
Hepatic Artery Infusion ◽  
Special Focus ◽  
Infusion Chemotherapy ◽  
Study Results ◽  
Hepatic Artery Infusion Chemotherapy ◽  
Metastatic Liver Tumors ◽  
Metastatic Liver

Malignancy with liver metastasis plays an important role in daily oncology practice, especially for primary cancers of the gastrointestinal tract and hepatopancreatobiliary system. On account of the dual vascular supply system and the fact that most metastatic liver tumors are supplied by the hepatic artery, hepatic artery infusion chemotherapy (HAIC) is an appealing method for the treatment of liver metastases. Herein, we summarize recent study results reported in the literature regarding the use of HAIC for metastatic liver tumors, with special focus on colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document